Abbott India Limited vs Laurus Labs Limited
Put two companies head-to-head — source-verified financials and AI-analysed SWOT, together in one view.
Abbott India Limited (Pharmaceuticals) and Laurus Labs Limited (Pharmaceuticals and contract development/manufacturing) go head-to-head here — with source-verified financials and a full SWOT breakdown side by side on Nexvora Intelligence. On the figures reported, Abbott India Limited leads on Revenue (approx.).
Abbott India Limited leads on Revenue (approx.).
Choose Abbott India if you prefer a branded domestic formulations business with strong parentage, recognized chronic and specialty brands, and an established doctor and pharmacy network. Choose Laurus Labs if you want exposure to manufacturing-led pharmaceuticals, antiretroviral APIs and formulations, and a growing CDMO/custom synthesis platform. The right choice depends on whether the buyer prioritizes branded Indian market stability versus integrated manufacturing and CDMO growth, while weighing each company’s respective pricing, regulatory, and concentration risks.
Grounded in the verified figures and SWOT shown — guidance, not investment advice.
Head-to-head highlights
| Metric | Abbott India Limited | Laurus Labs Limited | Basis |
|---|---|---|---|
| Revenue (approx.) | INR 5,800-6,200 crore | Around INR 5,000 crore, approximate and unverified | AI estimate |
An arrow marks the larger reported figure — a factual comparison, not a quality judgement. Verified figures come from official filings; AI estimates are approximate and unverified.
Abbott India Limited
Pharmaceuticals · India
Abbott India Limited is an Indian pharmaceutical company and a listed subsidiary of Abbott Laboratories. It markets branded prescription and over-the-counter healthcare products across therapeutic areas such as gastroenterology, women's health, metabolic disorders, central nervous system, pain management, and vaccines.
Verified financials
No source-verified financials available.
Strengths
- Strong parentage from Abbott Laboratories
- Recognized brands in chronic and specialty therapeutic areas
- Established doctor and pharmacy distribution network
- Focus on higher-margin branded formulations
Weaknesses
- High dependence on the Indian domestic pharmaceutical market
- Limited scale compared with India's largest pharma companies
- Exposure to price controls on essential medicines
- Relatively concentrated portfolio in select therapies
Opportunities
- Growth in chronic disease treatment demand in India
- Expansion in women's health, gastroenterology, and metabolic care
- Digital engagement with physicians and patients
- Leveraging Abbott's global portfolio for India-specific launches
Threats
- Intense competition from Indian generic and branded-generic companies
- Regulatory pricing pressure from India's drug price control regime
- Changes in physician prescribing behavior
- Supply chain and input cost volatility
Laurus Labs Limited
Pharmaceuticals and contract development/manufacturing · India
Laurus Labs Limited is an Indian pharmaceutical company focused on active pharmaceutical ingredients, finished dosage formulations, and contract development and manufacturing services. The company is known for its presence in antiretroviral medicines and has been expanding into non-ARV APIs, CDMO services, biotechnology, and specialty ingredients.
Verified financials
No source-verified financials available.
Strengths
- Strong chemistry and manufacturing capabilities
- Established presence in antiretroviral APIs and formulations
- Growing CDMO and custom synthesis platform
- Integrated operations across APIs and finished dosage forms
Weaknesses
- Exposure to pricing pressure in commoditized pharmaceutical products
- Dependence on regulated-market compliance and inspections
- Revenue volatility from project-based CDMO work
- Margin sensitivity to raw material and energy costs
Opportunities
- Expansion in CDMO and custom synthesis for global pharma clients
- Diversification into non-ARV therapies and specialty APIs
- Growth in biotechnology and fermentation-based manufacturing
- Increased demand for India-based pharmaceutical supply chains
Threats
- Regulatory actions or compliance setbacks
- Intense competition from Indian and Chinese manufacturers
- Customer concentration in certain product areas
- Currency fluctuations and global pricing pressure
Frequently asked
Answered from source-verified figures on this page.
Abbott India Limited vs Laurus Labs Limited: which company leads overall?
Abbott India Limited leads on Revenue (approx.).
Related market reports
Deep-dive intelligence on the markets these companies compete in.
India Defense Equipment Market — Intelligence Report
India Semiconductor Market — Chip Manufacturing, Electronics Ecosystem & Investment Outlook
Global Industrial Automation & Robotics Market — Intelligence Report
India Protein Industry Outlook — Intelligence Report
AI Analyst
Insights and answers generated live from Abbott India Limited vs Laurus Labs Limited's verified data. Modeled estimates — not investment advice.
- Abbott India Limited is a listed Indian subsidiary of Abbott Laboratories that markets branded prescription and over-the-counter healthcare products.
- Abbott India Limited operates across therapeutic areas including gastroenterology, women's health, metabolic disorders, central nervous system, pain management, and vaccines.
- Laurus Labs Limited is an Indian pharmaceutical company focused on active pharmaceutical ingredients, finished dosage formulations, and contract development and manufacturing services.
- Notable point: Laurus Labs Limited is known for antiretroviral medicines and has been expanding into non-ARV APIs, CDMO services, biotechnology, and specialty ingredients.